Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Oncologist - United States
doi 10.1634/theoncologist.2018-0344
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11

Oncotarget
Oncology
2018English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

Oncologist
Cancer ResearchMedicineOncology
2017English

Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy